Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Needle-free intradermal versus intramuscular fractional-dose Moderna booster after prior mRNA COVID-19 vaccination
NL-OMON51606Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: SARS-CoV-2 spike protein-specific binding IgG antibody levels, Local reactions and 5 more. Started May 2022; status: active, not recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51606.